640 related articles for article (PubMed ID: 31104023)
1. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
[TBL] [Abstract][Full Text] [Related]
2. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
[TBL] [Abstract][Full Text] [Related]
3. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
Hatashita S; Yamasaki H
PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
[TBL] [Abstract][Full Text] [Related]
5. The use of PIB-PET as a dual pathological and functional biomarker in AD.
Forsberg A; Engler H; Blomquist G; Långström B; Nordberg A
Biochim Biophys Acta; 2012 Mar; 1822(3):380-5. PubMed ID: 22115832
[TBL] [Abstract][Full Text] [Related]
6. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies.
Peretti DE; Vállez García D; Reesink FE; van der Goot T; De Deyn PP; de Jong BM; Dierckx RAJO; Boellaard R
PLoS One; 2019; 14(1):e0211000. PubMed ID: 30653612
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
[TBL] [Abstract][Full Text] [Related]
8. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
9. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
[TBL] [Abstract][Full Text] [Related]
11. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
[TBL] [Abstract][Full Text] [Related]
12. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia.
Rabinovici GD; Jagust WJ; Furst AJ; Ogar JM; Racine CA; Mormino EC; O'Neil JP; Lal RA; Dronkers NF; Miller BL; Gorno-Tempini ML
Ann Neurol; 2008 Oct; 64(4):388-401. PubMed ID: 18991338
[TBL] [Abstract][Full Text] [Related]
13. Early after Administration [11C]PiB PET Images Correlate with Cognitive Dysfunction Measured by the CERAD Test Battery.
Tiepolt S; Luthardt J; Patt M; Hesse S; Hoffmann KT; Weise D; Gertz HJ; Sabri O; Barthel H
J Alzheimers Dis; 2019; 68(1):65-76. PubMed ID: 30636731
[TBL] [Abstract][Full Text] [Related]
14. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
15. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
[TBL] [Abstract][Full Text] [Related]
16. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
[TBL] [Abstract][Full Text] [Related]
17. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
18. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum.
Nihashi T; Sakurai K; Kato T; Iwata K; Kimura Y; Ikenuma H; Yamaoka A; Takeda A; Arahata Y; Washimi Y; Suzuki K; Bundo M; Sakurai T; Okamura N; Yanai K; Ito K; Nakamura A;
J Alzheimers Dis; 2022; 85(1):223-234. PubMed ID: 34776443
[TBL] [Abstract][Full Text] [Related]
20. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]